A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- Registration Number
- NCT00002440
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV drugs. This study also examines how the body processes these drugs when they are given together.
- Detailed Description
In this Phase II, open-label study patients (16 per treatment group) are randomized to receive 1592U89 in combination with one of five protease inhibitors: indinavir, saquinavir, ritonavir, nelfinavir, or 141W94 for up to 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (8)
UCSD Treatment Ctr
🇺🇸San Diego, California, United States
Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit
🇺🇸New Haven, Connecticut, United States
Kansas City AIDS Research Consortium
🇺🇸Kansas City, Missouri, United States
NYU Med Ctr / Dept of Medicine / AIDS Clinical Trial
🇺🇸New York, New York, United States
Carolinas Med Ctr
🇺🇸Charlotte, North Carolina, United States
Case Western Reserve Univ / AIDS Clinical Trials Unit
🇺🇸Cleveland, Ohio, United States
Univ of Pittsburgh Med Ctr
🇺🇸Pittsburgh, Pennsylvania, United States
Vanderbilt Univ Med Ctr
🇺🇸Nashville, Tennessee, United States
UCSD Treatment Ctr🇺🇸San Diego, California, United States